Clearmind’s Psychedelic CMND-100 Arrives in US for Yale Trial
Clearmind Medicine Inc. (Nasdaq: CMND) has shipped its novel psychedelic-derived drug candidate, CMND-100, to the United States for its...
Silexion Unveils Sil204 Plan at NEAUXCancer 2025
Silexion Therapeutics has developed an expanded plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The company will...
Opthea Coast Phase 3 Trial Fails to Meet Primary Endpoint
Opthea Limited’s Phase 3 COAST trial for sozinibercept, a combination therapy with aflibercept for wet age-related macular degeneration (wet...
Pharma’s Future: Graham Clark on Trends and Challenges
In the dynamic world of pharmaceuticals, staying ahead of trends and challenges is vital. Graham Clark, CEO of Phastar,...
Nanobiotix Data from Two Phase 1 NBTXR3 Studies at ELC
Nanobiotix announced two poster presentations at the 2025 European Lung Cancer Conference showcasing Phase 1 study data for JNJ-1900...
CEPI Funds Dyadic’s C1 for Protein Vaccine Development
Dyadic International received a $4.5 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore using their...
Briacell’s Phase 3 Breast Cancer Study Gets Positive Recommendation
BriaCell Therapeutics Corp. announced positive safety results from the second review of its Phase 3 study of Bria-IMT™ combined...
Medera Gets DSMB Clearance to Advance Phase 2 Portion of Phase 1b/2 Trial for Gene Therapy in Heart Failure
Medera Inc., a clinical-stage biopharmaceutical company, announced positive results from the Phase 1b portion of its MUSIC-HFrEF trial, evaluating...
Soquelitinib Data in T-Cell Lymphoma: Promising Results Unveiled
Corvus Pharmaceuticals released additional data from its Phase 1/1b clinical trial of soquelitinib, an oral ITK inhibitor, for T-cell...
Pathos AI Doses First Patient in Pocenbrodib Trial
Pathos AI has initiated a Phase 1b/2a clinical trial for its CBP/p300 inhibitor, pocenbrodib, in patients with metastatic castration-resistant...